122 related articles for article (PubMed ID: 2959889)
1. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
[TBL] [Abstract][Full Text] [Related]
2. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
3. The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer.
Schwendener RA
Cancer Drug Deliv; 1986; 3(2):123-9. PubMed ID: 2939941
[TBL] [Abstract][Full Text] [Related]
4. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
5. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
Schwendener RA; Schott H
Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
[TBL] [Abstract][Full Text] [Related]
6. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
7. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
9. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
10. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
11. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
[TBL] [Abstract][Full Text] [Related]
12. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia].
Fu NW
Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312
[TBL] [Abstract][Full Text] [Related]
13. Chromatography of functionalized liposomes and their components.
Schott H; Leitner B; Schwendener RA; Hengartner H
J Chromatogr; 1988 May; 441(1):115-24. PubMed ID: 3403675
[TBL] [Abstract][Full Text] [Related]
14. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
15. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Schwendener R; Schott H
Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA; Fiebig HH; Berger MR; Berger DP
Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
[TBL] [Abstract][Full Text] [Related]
17. [Antileukemic activity of liposome forms of cytosine arabinoside and cyclocytidine].
Reshchikov VP; Afonin NI; Ermakov LN; Fertukova NM; Oksinoĭd OE
Gematol Transfuziol; 1984; 29(5):49-51. PubMed ID: 6203808
[No Abstract] [Full Text] [Related]
18. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
Kobayashi T; Tsukagoshi S; Sakurai Y
Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
[No Abstract] [Full Text] [Related]
19. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
20. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
[No Abstract] [Full Text] [Related]
[Next] [New Search]
